A phase-one clinical trial in 30 patients with advanced tumours is expected to start in 2020 across a number of US cancer centres.
Showing 25 of 1915
This follows the manufacturing licence granted in June 2019 for its Bundaberg facility.
HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours in gastric, breast, ovarian, lung and pancreatic cancers.
Advangen is the company’s wholly-owned subsidiary engaged in development and sale of first in class, best in class clinically validated anti-ageing products.
The company is focused on creating commercial opportunities that will generate potential revenue from early sales of finished product or through partnering/commercial transactions.
A new collaboration with the Alliance for clinical trials in oncology means Kazia will soon have four clinical trials of GDC-0084 underway in primary or secondary brain cancers.
The biopharmaceutical company now has 65 patents either in force or pending in most major countries around the globe covering its lead drug candidate PRP
In addition to its core Australian medicinal cannabis assets, THC has a significant Canadian presence – both in cannabis and in hydroponics equipment.
If Bronchitol is approved by the US FDA, Pharmaxis will receive US$10 million.
Eve Investments, via agreements with THC Global, now has a viable option to access THC’s cannabis licensing for research and development of its products.
Receipt of the third and final cannabis licence underlines the company’s position as a leader in the medicinal cannabis sector in Australia.
Results were presented at the ASCO annual meeting in Chicago, which attracts over 40,000 cancer specialists.
The trial was treating patients with joint pain or joint stiffness.
The sale enables Admedus to focus its growth and development strategy around its key ADAPT® product portfolio of biomaterial scaffolds used in heart valve repairs.
The company has a clear path towards leading the Australian cannabis market to produce high-grade pharmaceutical medical cannabis products.
The new CEO’s mandate is to accelerate partnering discussions and explore opportunities to fully exploit the midkine assets.
Doctors can administer the treatment to patients under the TGA Special Access Scheme.
The study will mark the fourth ongoing clinical trial for Kazia's GDC-0084 drug candidate, with each trial treating different forms of brain cancer.
The company is also expanding the total leased land for its Northern NSW cannabis cultivation site up to 150,000 square metres.
The restructure will enable the company to improve working capital management and reduce cash burn through reduction in headcount.
If Bronchitol is approved later this year, Pharmaxis is down to receive US$10 million.
The company will begin recruitment for the upcoming dose expansion cohort immediately.
The company’s O2 Vent Optima device was launched in both Australia and Canada during the March quarter.
The oncology-focused biotech is a mid-clinical-stage therapeutics company.
The évolis® professional products can now be imported into EU countries and the UK following comprehensive safety and compliance reviews.